BofA Securities downgraded GoodRx from Buy to Underperform and set a new price target of $4.50 from $8.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $5.00 | Neutral | Mizuho |
| 8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
| 5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
| 4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
| 3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
| 2/26/2024 | $8.00 | Outperform | Leerink Partners |
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
144 - GoodRx Holdings, Inc. (0001809519) (Subject)
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve
The all-in-one solution includes virtual consultation, FDA-approved prescription medication, and discreet home delivery, with no hidden fees, in-person visits, or memberships required GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription service for erectile dysfunction (ED). Designed to meet consumers where they are and remove common barriers such as high costs, long wait times, and inconvenience, this all-in-one solution offers a fast, discreet, and affordable option for ED treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610400981/en/ A ne
Community Link allows independent pharmacies to direct contract with GoodRx, manage participation in the company's Integrated Savings Program, and access over 90 brand medication partnership offerings Cost-plus pricing is anchored on NADAC Starting July 1, all independent pharmacies will be opted out of GoodRx's Integrated Savings Program by default GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the industry challenges that independent community pharmacies face around complex reimbursement models and competitive pressures, Community Link leverages a cost-plus pricing model based on
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for
Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy
Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve
First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel